Literature DB >> 17390255

Neuroprotection in Parkinson's disease: an elusive goal.

Kevin M Biglan1, Bernard Ravina.   

Abstract

Despite increases in our understanding of the pathophysiology and environmental and genetic influences of illness in Parkinson's disease, neuroprotection remains an elusive goal. No interventions are widely accepted as disease modifying in Parkinson's disease. Continued research identifying novel therapeutic targets is likely to result in several putative neuroprotective agents. Assimilating lessons from previous neuroprotection trials will be critical in developing future trials aimed at efficiently identifying neuroprotective treatments. Ultimately, overcoming the unique challenges of a heterogenous, slowly progressive disorder with multiple potential outcome measures will be necessary to identify treatments that have meaningful effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390255     DOI: 10.1055/s-2007-971168

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  8 in total

Review 1.  Neuroprotection in Parkinson's disease: myth or reality?

Authors:  Tiffini Voss; Bernard Ravina
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

2.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

Review 3.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

4.  The futility study--Progress over the last decade.

Authors:  Bruce Levin
Journal:  Contemp Clin Trials       Date:  2015-06-26       Impact factor: 2.226

Review 5.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

Authors:  Isaac G Onyango
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

6.  Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations.

Authors:  Jonathan Kimmelman; Alex John London; Bernard Ravina; Tim Ramsay; Mark Bernstein; Alan Fine; Frank W Stahnisch; Marina Elena Emborg
Journal:  Mov Disord       Date:  2009-10-15       Impact factor: 10.338

7.  Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease.

Authors:  Connie Marras; Kelly A Mills; Shirley Eberly; David Oakes; Kelvin L Chou; Matthew Halverson; Sotirios A Parashos; Christopher G Tarolli; Jin-Shei Lai; Cindy J Nowinsky; Oksana Suchowersky; Eric S Farbman; Lisa M Shulman; Tanya Simuni
Journal:  Mov Disord       Date:  2021-05-13       Impact factor: 9.698

8.  Rasagiline in treatment of Parkinson's disease.

Authors:  Lakshmi Nayak; Claire Henchcliffe
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.